CN Patent

CN101330919B — 包含(e)-7-[4-(4-氟苯基)-6-异丙基-2-[甲基(甲磺酰基)氨基]嘧啶-5-基]-(3r,5s)-3,5-二羟基庚-6-烯酸的药物组合物

Assigned to Lek Pharmaceuticals dd · Expires 2012-12-05 · 13y expired

What this patent protects

应用起稳定作用从而阻止降解产物(内酯和氧化产物)形成的物质，开发了用于口服使用的(E)-7-[4-(4-氟苯基)-6-异丙基-2-[甲基(甲磺酰基)氨基]嘧啶-5-基]-(3R，5S)-3，5-二羟基庚-6-烯酸或其药学上可接受的盐的化学稳定制剂，例如片剂、胶囊剂、散剂、颗粒剂。

USPTO Abstract

应用起稳定作用从而阻止降解产物(内酯和氧化产物)形成的物质，开发了用于口服使用的(E)-7-[4-(4-氟苯基)-6-异丙基-2-[甲基(甲磺酰基)氨基]嘧啶-5-基]-(3R，5S)-3，5-二羟基庚-6-烯酸或其药学上可接受的盐的化学稳定制剂，例如片剂、胶囊剂、散剂、颗粒剂。

Drugs covered by this patent

Patent Metadata

Patent number
CN101330919B
Jurisdiction
CN
Classification
—
Expires
2012-12-05
Drug substance claim
No
Drug product claim
No
Assignee
Lek Pharmaceuticals dd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.